Hercules Offshore, Inc. (NASDAQ:HERO) on Thursday closed at $0.49. Stock institutional ownership is 51.50% while insider ownership includes 3.40%. Hercules Offshore, Inc. (NASDAQ:HERO) distance from 50-day simple moving average (SMA50) is -27.16%. On 2 April, Hercules Offshore, Inc. (NASDAQ:HERO) announced that it has signed a five-year contract with a subsidiary of Eni S.p.A. for use of the Hercules 260 in West Africa.
QUALCOMM, Inc. (NASDAQ:QCOM) in last trading activity decreased -2.10% to close at $67.97. Company weekly performance is 1.21% while its quarterly performance stands at -8.02%. QUALCOMM, Inc. (NASDAQ:QCOM) is -15.64% away from its 52 week high. On 2 April, QUALCOMM, Inc. (NASDAQ:QCOM) commenced the company’s annual QPrize™ 2015 international seed investment competition. The competition aims to identify and provide seed funding into early-stage companies with unique and promising wireless technologies. Entrepreneurs in countries or regions that include Australia, China, Europe, India, Israel, Korea, Latin America and North America are eligible to apply and participate in the QPrize competition.
On last trading day Fulton Financial Corporation (NASDAQ:FULT) moved up 0.32% to close at $12.37. Its volatility for the week is 1.40% while volatility for the month is 1.97%. FULT’s sales growth for past 5 years was -5.40% and its EPS growth for past 5 years was 22.10%. Fulton Financial Corporation (NASDAQ:FULT) monthly performance is 3.26%. Fulton Financial Corporation (NASDAQ:FULT) has been given a “BBB+” credit rating by Morningstar. The investment research firm’s “BBB+” rating suggests that the company is a moderate default risk. They also gave their stock a two star rating.
On Thursday shares of Galena Biopharma Inc (NASDAQ:GALE) closed at $1.37.Galena Biopharma Inc (NASDAQ:GALE) announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 14th Annual Needham Healthcare Conference. The presentation will take place on Tuesday, April 14, 2015 at 10:40 a.m. ET at The Westin Grand Central Hotel in New York, NY.
Merck & Co. Inc. (NYSE:MRK) in last trading activity increased 0.42% to close at $57.10. Company weekly performance is -0.87% while its quarterly performance stands at 1.37%. Merck & Co. Inc. (NYSE:MRK) is -9.52% away from its 52 week high. On 1 April, Merck & Co. Inc. (NYSE:MRK) has reached an agreement to test Keytruda (pembrolizumab)alongside Syndax’s histone deacetylase (HDAC) inhibitor entinostat in phase Ib/II trials in melanoma and non-small cell lung cancer (NSCLC), with a view to progressing quickly to full-blown phase III studies.